Introduction
The 2013-2016 epidemic of Ebola virus (EBOV) disease in West Africa, with over 28,000 confirmed or suspected cases and over 11,000 deaths, highlights the need for effective pharmacologic therapies to reduce viral replication and treat the consequences of infection. Despite efforts to develop vaccines and antivirals, there are currently no licensed drugs for the treatment of EBOV and other filovirus diseases. Given the difficulty in conducting clinical trials and the unpredictable timing of outbreaks, demonstrating efficacy in animal models of EVD such as nonhuman primates (NHPs) can be helpful to prioritize experimental medical countermeasures for use in clinical trials when outbreaks occur and potentially for registration under the FDA Animal Rule when clinical data cannot be obtained.
Favipiravir (T-705; 6-fluor-3-hydroxy-2-pyraxinecarboxamide) is a synthetic guanidine nucleoside analog that has demonstrated potent broad-spectrum antiviral activity in vitro and in vivo against multiple families of RNA viruses Julander et al., 2009a Julander et al., , 2009b Morrey et al., 2008; Oestereich et al., 2014a; Furuta et al., 2013) .
Favipiravir is licensed in Japan for the treatment of influenza, and safety and tolerability have been established in humans, making it a particularly attractive candidate for repurposing efforts. Favipiravir has also demonstrated efficacy in mouse models of EBOV infection when evaluated by USAMRIID and others (Oestereich et al., 2014b; Smither et al., 2014; Bixler et al., 2017) . During the 2013-2016 EBOV outbreak, favipiravir was evaluated in Phase II clinical trials for efficacy in West Africa (Sissoko et al., 2016; Bai et al., 2016) and was administered under compassionate use protocols to several patients, including one in combination with ZMab and another in combination with convalescent plasma (Schibler et al., 2015; Mora-Rillo et al., 2015) . A retrospective clinical case study in Sierra Leone found a survival benefit and reduction in viral loads associated with favipiravir treatment (Bai et al., 2016) . However, the results for a second historically-controlled study conducted in Guinea (JIKI trial) were inconclusive (Sissoko et al., 2016) . The results of that study suggested that favipiravir may have limited efficacy in patients with low to moderate levels of virus (Ct values ≥ 20) (Sissoko et al., 2016) and that efficacy may have been hampered by sub-optimal drug exposure in these patients .
Despite the availability of rodent data and the human clinical trial results that were made available in 2016, there are no published reports of the efficacy of favipiravir in an NHP model of EVD, which is considered the most relevant model for the human disease course and potentially more predictive of human efficacy (Bente et al., 2009) . During the height of the West African outbreak in 2014, we initiated studies of the activity of favipiravir against EBOV in cell culture and in mice (Bixler et al., 2017) . Having obtained encouraging results in the rodent model, we moved forward to assess favipiravir's protective effect in cynomolgus macaques infected with either EBOV or Marburg virus (MARV).
Materials and methods

Facilities
All animal studies were performed in BSL-4 containment facilities at USAMRIID. The facility where this research was conducted is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011.
Ethics statement
Research was conducted under IACUC-approved protocols in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to animals and experiments involving animals.
Experimental design of NHP efficacy studies
A total of three randomized NHP studies were performed. All studies used healthy cynomolgus macaques (Macaca fascicularis) of 4.5-6.5 years of age and weighing between 3.52 and 8.03 kg. The study designs, group designations, dosing regimens, and phlebotomy schedules are provided in detail as Fig. 1 and Table 1 . Animals were infected with a target dose of 1000 plaque-forming units (PFU) of either EBOV Kikwit (Studies 1 and 2) or MARV Angola (Study 3) by intramuscular (IM) injection.
Oral dosing
In Studies 1 and 2, NHPs were randomly assigned to receive favipiravir (Toyama Chemical Co., Ltd., Japan) suspended in 0.4% carboxymethylcellulose (CMC) (Spectrum Chemicals and Laboratory Products, New Brunswick, NJ) or 0.4% CMC vehicle only via oral administration (PO). Crystalline favipiravir drug substance was milled to a 12-14 μm particle size. In Studies 1 and 2, favipiravir and vehicle were administered to animals anesthetized with ketamine (100 mg/mL) and acepromazine (10 mg/mL) at 0.1 mL/kg IM. Doses were delivered by bolus administration via orogastric intubation and gavage tubing was flushed with water to ensure complete administration of the intended dose. In Study 1, favipiravir and vehicle were administered once-daily in a volume of 2.5 mL/kg body weight on day −3 and a volume of 1.25 mL/kg on days −2 through 10. In Study 2, animals received either vehicle or favipiravir in the same manner as Study 1 but twice-daily by oral gavage at approximately 12 h intervals, with the AM dose on day 0 administered 30-120 min after challenge. Because oral administration in NHPs in BSL-4 containment must be performed under anesthesia for safety reasons, animals in Studies 1 and 2 had repeated anesthesia events over the course of 14 days. Due to the altered dosing regimen in Study 2, the number of anesthesia events doubled during this time period. Repeated anesthesia events can place additional stress on animals, particularly those that are experiencing clinical signs of EVD. Therefore, repeated anesthesia due to oral dosing may represent a potential confounding factor that could influence survival outcome.
Intravenous dosing
To avoid the need for repeated anesthesia in BSL-4, intravenous dosing through the use of catheters, jackets, and tethering systems can be utilized. Prior to the start of Study 3, a new intravenous (IV) formulation of favipiravir in meglumine with improved exposure was made available. NHPs were randomly assigned to receive favipiravir dissolved in vehicle (7.46% meglumine in sterile water for injection) or vehicle only twice-daily by IV administration for 14 days using central venous catheters (CVCs). Animals were acclimated to Lomir primate jackets and tethering at BSL-2 at least 3 days prior to catheter insertion surgery. A single lumen Hickman CVC was inserted into the right jugular vein while the animals were anesthetized and intubated. Following surgery, radiology/fluoroscopy was used to confirm the correct placement of the catheter. Animals were subsequently placed in jackets and were allowed to recover for at least 5 days prior to transfer to BSL-4. The patency of the catheters was evaluated prior to transport into BSL-4. Group 1 received vehicle by bolus IV injection through the CVC. For Group 2, all favipiravir injections were administered as 20 min slow IV infusions through the CVC, followed by a flush using 0.9% sodium chloride for injection. On day 14, conduit tethers were removed from the jackets of all surviving animals. The infusion line was removed, the catheter was capped, and the end of the catheter was stored in the jacket's dorsal pocket.
In-life activities
Animals were observed at least twice-daily for clinical signs of disease and were euthanized, either when moribund or at the end of the in-life phase, by pentobarbital overdose administered via available peripheral vein under deep anesthesia. Physical examinations to include weights and rectal temperatures were performed whenever an animal was anesthetized. Blood samples were collected periodically (Table 1) for evaluation of secondary endpoints such as viral RNA, plasma favipiravir levels, and hematology, coagulation, and serum chemistry parameters. Any animals that survived until day 28 were designated as survivors and euthanized.
Quantitative real-time PCR
Viral-burden assessment was conducted on plasma samples on the days specified for blood collection noted in Fig. 1 and Table 1 for each NHP study. Quantitative real-time PCR (qRT-PCR) was used to evaluate viral RNA copy number as previously described (Warren et al., 2016) using primers and probes specific for either EBOV or MARV. Quantification of genome copies per volume of plasma was calculated from the cycle-threshold value obtained for each sample compared using the standard-curve equation. The lower limit of quantification for the qRT-PCR analysis for EBOV and MARV was 8.0 × 10 4 and 8.0 × 10 5 copies/ mL of plasma, respectively.
Quantification of favipiravir and M1 levels in NHPs
Favipiravir and metabolite 1 (M1) levels were assessed in treated NHPs. In Study 1, blood was collected at pre-treatment and 1 h posttreatment on days −2, 1, 2 and 5. In Study 2, blood was collected immediately prior to AM treatment on days 3 and 7. In Study 3, blood was collected at pre-and post-treatment on days 3, 6, and 9 and on days 14 and 28. Within BSL-4 containment, 10 μL of internal standard (IS) solution (100 ng/μL of 6-chloro-3-hydroxypyrazine-2-carboxamide in HPLC Mobile Phase A buffer) was spiked into 100 μL of plasma and allowed to equilibrate for 10 min at room temperature (RT). Following IS addition, 500 μL of absolute ethanol was added, samples briefly mixed and allowed to stand for 10 min at RT. The ethanol precipitated serum proteins were cleared by centrifugation at 19,000 × g for 15 min. Supernatant (300 μL) was transferred to a clean polypropylene tube and allowed to passively dry in a biological safety cabinet over 48 h. Once dry, 50 μL of acetonitrile and 50 μL of 70% formic acid were added, samples vortexed, capped, transferred to a BSL-2 laboratory and allowed to dry overnight in a biological safety cabinet. Safety testing data supports the complete inactivation of Ebola following this protocol. Upon dryness, 100 μL HPLC Mobile Phase A buffer was added, samples were vortexed, briefly centrifuged to collect liquid and transferred to low volume autosampler vials for HPLC analysis. HPLC Mobile Phase A consisted of 0.8% triethylamine buffer (prepared from an 8% TEA stock that was pH adjusted to 7.0 with acetic acid) and 5% methanol. Mobile Phase B consisted of 0.8% triethylamine buffer (prepared from an 8% TEA stock that was pH adjusted to 7.0 with acetic acid) and 20% methanol. HPLC experiments were conducted on an Agilent 1200 instrument equipped with a diode array UV detector and utilized an Intersil ODS-3 column (4.6 mm × 100 mm, 3 μm) (GI Sciences). Analytes were detected by monitoring absorbance at 360 nm and separations were conducted at a column temperature of 30°C with a flow rate of 1 mL/min. Mobile phase composition was varied as follows. The column was equilibrated with 100% HPLC Mobile Phase A prior to sample addition, and upon sample addition, a nine minute linear Group 1: 0 mg/kg BID days 1-13 Group 2: 150 mg/kg BID days 1-13 0, 3, 6, 9, 14, 21, and euthanasia S.L. Bixler et al. Antiviral Research 151 (2018) 97-104 gradient to 100% Mobile Phase B was used to separate analytes. The column was then re-equilibrated with 100% Mobile Phase A for 5 min prior to the injection of the next sample. The primary metabolite M1, favipiravir and IS peaks eluted at 2.8, 3.6, and 5.9 min, respectively. Analyte peaks were integrated with ChemStation software (Agilent) to determine the peak areas. The concentrations of the analytes in unknown samples were determined from standard curves generated using known concentrations of IS and favipiravir. The limit of quantification of the assay was 0.1 μg/mL and the analyte concentration could be determined with an accuracy of ± 10%.
Clinical pathology
Serum chemistry analysis was conducted using a VITROS ® 350
Chemistry System (Ortho Clinical Diagnostics). Analysis of coagulation parameters was conducted using a Sysmex CA-1500. Hematology analysis was performed on an Advia 120 Hematology Analyzer (Siemens) with multispecies software.
Pathology
Necropsies, tissue collection, and tissue processing were performed as previously described (Warren et al., 2016) . Histology and immunohistochemistry for the detection of EBOV or MARV antigen were performed on designated tissues (Warren et al., 2016) . A subset of tissues were examined for bacteria by staining deparaffinized tissue sections in crystal violet for 1 min, rinsing, and then staining with Lugol's iodine for 1 min. The tissue sections were counterstained with neutral red/fast green and coverslipped (Gram-Twort stain). Select samples were examined for argyrophilic bacteria, specifically spirochetes, by covering deparaffinized tissue sections with 1% Silver Nitrate for 3 min followed by exposure to developer (Warthin Starry stain).
Statistical analyses
Kaplan-Meier survival curves were generated using Prism GraphPad software (version 6.04) and compared by the Log-rank (Mantel-Cox) test. Wilcoxon rank-sum test and Kruskal-Wallus test with Dunn's multiple comparisons test were used for analysis of clinical chemistry parameters.
Results
Efficacy of once-daily oral treatment of EBOV infection in NHPs
To assess the efficacy of oral favipiravir against EBOV infection of NHPs, cynomolgus macaques (n = 12) were exposed to EBOV on day 0 and treated with either favipiravir (n = 6) or vehicle (n = 6) starting three days prior to virus exposure and continuing once-daily through day 10. All vehicle-control animals succumbed between day 7 and day 10 (Fig. 2a) . One of the six (17%) animals in the favipiravir-treated group survived; three of the remaining animals succumbed on days 10 and 12 while two succumbed on day 17. The mean time-to-death for the favipiravir-treated group (13.2 days) was significantly delayed as compared to the vehicle-control group (8.5 days; p value = 0.0138). All animals that succumbed, regardless of treatment status, had clinical signs consistent with typical EVD that we and others have observed in this model, including rash and fever (Bente et al., 2009; Shurtleff and Bavari, 2015; Warren et al., 2014) . While similar signs of disease were also observed in the sole survivor, this animal ultimately recovered.
Viral RNA was first detected in vehicle-control animals on day 5 and in favipiravir-treated animals on day 7 (Fig. 3a) . On these days, the mean viral load in treated animals was over 10-fold lower compared to vehicle-controls. Viral RNA levels increased from day 9 to days 10 and 14; given that cessation of favipiravir treatment occurred on day 10, the increases in viral RNA from day 9 to day 14 in three animals, two of which succumbed on day 17, is suggestive of viral recrudescence. In the sole favipiravir-treated survivor, viral RNA was undetectable after day 14.
To determine if sufficient drug exposure was achieved, favipiravir and major metabolite (M1) levels were measured in the plasma of treated animals (Bixler et al., 2017) . Plasma favipiravir levels at 1 h post-treatment on days −2, 1, 2, and 5 ranged from 175 to 231 μg/mL and M1 levels ranged from 19 to 37 μg/mL. At 24 h post-dose (pretreatment), plasma favipiravir levels ranged from 2 to 10 μg/mL (Table 2) . While the post-treatment levels are well-above the EC 50 (44.2 μg/mL; (Bixler et al., 2017) ), the relationship between plasma favipiravir/M1 and intracellular tri-phosphate levels has not been fully characterized in NHPs.
Typical alterations in clinical pathology parameters associated with filoviruses were noted in both vehicle-control and favipiravir-treated animals, including elevated liver enzymes, thrombocytopenia, and increased expression of markers of coagulopathy. However, such alterations were less pronounced in favipiravir-treated animals as compared to vehicle-controls. At day 7, statistically significant differences were noted for the changes in AST, CRE, and TT levels between controls and favipiravir-treated animals (Table 3 ). While differences in other clinical chemistry parameters such as ALT and platelets were also noted, these differences were not statistically significant. The sole favipiravir-treated survivor developed many of the same alterations as seen in the nonsurvivors; however, they resolved to within normal limits by the end of the in-life phase.
In general, the postmortem lesions in the non-survivors were consistent with typical EVD in NHPs and were similar in nature regardless of treatment status or time-to-death. The most common postmortem S.L. Bixler et al. Antiviral Research 151 (2018) 97-104 changes included macular skin rash, lymph node enlargement, and lesions in the liver, spleen, kidney, and adrenal gland. Additionally, all non-survivors had similar histologic evidence of active EBOV infection including lymphoid depletion, lymphocytolysis, hepatocellular degeneration and necrosis, and abundant viral antigen as detected by IHC. Although histologic lesions and viral antigen were present in the treated animals that succumbed, they were notably less severe and intense than those in control animals that died at similar time points. At day 28, the sole favipiravir-treated survivor had no gross evidence of viral infection or viral antigen in any tissues. Gastrointestinal pathology not typically seen in experimental EBOV infection of NHPs was noted in three animals (1 vehicle-control; 2 favipiravir-treated) including intussusception, enterocyte necrosis, mucosal/lamina propria hemorrhage with loss of intestinal enterocytes, basophilic debris within the crypts, and colitis with invasion of numerous gram-negative bacteria. A prominent basophilic microvillar border and the presence of spirochetes within colonic lesions were noted in several animals, suggestive of a concurrent bacterial infection.
Efficacy of twice-daily oral treatment of EBOV infection in NHPs
To determine if more frequent oral dosing could lead to improved survival, a second study was conducted in which favipiravir was administered twice-daily. A total of eighteen cynomolgus macaques (n = 18) were exposed to EBOV on day 0 and treated with either favipiravir (n = 12) or vehicle (n = 6) initiated shortly after infection and continuing through day 13. Two dosing regimens were evaluated: 250 mg/kg loading dose and 125 mg/kg favipiravir twice-daily (n = 6) or 125 mg/kg loading dose and 75 mg/kg twice-daily (n = 6). All vehicle-control animals (Group 1) succumbed between day 6 and day 10 (Fig. 2b) . All favipiravir-treated animals in Group 2 (250/125 mg/ kg) succumbed on days 11 and 15 while all Group 3 animals (125/ 75 mg/kg) succumbed between days 8 and 11. The mean time-to-death for favipiravir-treated animals in Groups 2 and 3 (14 and 9.7 days, respectively) was significantly increased as compared to the vehiclecontrols (7.2 days; P values = 0.0001 and 0.0054, respectively). Although favipiravir was administered more frequently in this study, twice-daily oral administration also required an additional anesthesia event each day, which may have placed additional stress on ill animals.
Plasma favipiravir levels immediately prior to administration of the AM dose on days 3 and 7 for Group 2 were 228 and 159 μg/mL, respectively, and the major metabolite (M1) levels were low, i.e., 6-8 μg/ mL (Table 4) . Consistent with the lower dosing regimen, plasma favipiravir and M1 levels were between 3-6 μg/mL and < 1 μg/mL respectively in Group 3 animals.
Dose-dependent changes in other markers of disease, such as viral RNA levels and clinical pathology parameters, were also observed in the favipiravir-treated animals. On day 5, the mean viral RNA concentrations in Group 2 and Group 3 were reduced by 1000-fold and 10-fold respectively as compared to vehicle-controls (Fig. 3b) . Alterations in serum chemistry, coagulation, and hematology were similar to those observed in the once-daily dosing study; such changes were also less pronounced in favipiravir-treated animals and were often dependent on favipiravir dose (Table 3) .
Postmortem lesions indicative of EBOV infection were present in all animals regardless of group designation and were similar to those noted in the once-daily dosing study. However, favipiravir-treated animals with a delayed time-to-death generally had fewer filoviral-associated gross and histologic lesions. While EBOV antigen was detected by IHC in all NHPs regardless of treatment status, favipiravir-treated animals (Groups 2 and 3) had reduced viral antigen staining as compared to the vehicle-control animals, especially in the liver and spleen. The most notable difference between vehicle-control and favipiravir-treated animals was the presence of lesions within the gastrointestinal tract, which Fig. 3 . Viral RNA levels in plasma. Mean log10 genome copies/mL of plasma in the oncedaily EBOV (a), twice-daily EBOV (b), and twice-daily MARV (c) NHP studies. Lower limit of quantitation (4.90 log10 genome copies/mL for EBOV; 5.90 log10 genome copies/mL for MARV) and limit of detection (3.0 log10 genome copies/mL) are denoted by the dashed lines. The gray shaded area indicates the duration of treatment. Antiviral Research 151 (2018) 97-104 were similar to those observed in Study 1 and had positive staining for bacterial spirochetes. A causal relationship between gastrointestinal lesions and favipiravir treatment cannot be determined from the available data.
Efficacy of twice-daily IV treatment of MARV infection in NHPs
The efficacy of favipiravir was assessed against MARV, a closely related filovirus. In lieu of oral dosing, animals in this study were administered intravenous favipiravir twice-daily starting shortly after infection and continuing through day 13. Prior to the start of the study, animals were catheterized and acclimated to the use of Lomir jackets and tethers. The switch from oral to intravenous dosing, along with the use of this system, eliminated the need for repeated anesthesia events, particularly during the critical disease phase. All vehicle-control animals (Group 1) succumbed between days 7 and 9, while five out of six treated animals (83%) survived until the end of the study (Fig. 2c) . The time-to-death for the sole favipiravir-treated animal that succumbed (14.0 days) was markedly delayed as compared to vehicle-controls (8.2 days).
Viral RNA was first detected in vehicle-control animals on day 3 and in favipiravir-treated animals on day 6 (Fig. 3c) . On day 6, mean viral RNA levels were reduced by greater than 10,000-fold in the treated animals (3.57 × 10 7 genome copies/mL) as compared to vehicle-controls (4.08 × 10 11 genome copies/mL). While viral RNA was detected in four of the six treated animals on day 9, the only animal with levels of viral RNA remaining on day 14 was the one that succumbed at that time. Similar alterations in hematology, coagulation, and serum chemistry parameters were noted in the non-survivors in this study as those observed in the two EBOV studies (Table 3 ). In general, the changes observed in the sole favipiravir-treated animal that succumbed to MARV infection were of the same magnitude as the vehicle-controls. However, while alterations in these parameters were first noted as early as day 3 in controls, their appearance was delayed to day 9 in the treated non-survivor. In the surviving animals, favipiravir treatment resulted in a statistically significant decrease in many of the hallmark effects of filovirus disease, including less dramatic alterations in AST and ALT levels (Table 3) .
Favipiravir levels prior to administration of the AM dose on days 3, 6, and 9 were 13-40.1 μg/mL, 4.3-46.1 μg/mL, and 5.9-38.1 μg/mL, respectively, while M1 levels were 1.8-3.7 μg/mL, 0.9-4.1 μg/mL, and 1.1-3.8 μg/mL, respectively (Table 5) . As expected, favipiravir and M1 levels were notably higher post-administration on days, 3, 6, and 9; favipiravir levels were 268.2-339.8 μg/mL, 250-337.2 μg/mL, and 236.2-362.4 μg/mL, respectively, while M1 levels were 7.6-201. μg/mL, 8.9-26.8 μg/mL, and 11.1-26.7 μg/mL. While levels of favipiravir and M1 were still detectable in many of the animals on day 14 (1.1-153.5 μg/mL and 0.8-14.9 μg/mL, respectively), levels were markedly reduced and nearly undetectable on day 28 (0.1-3.1 μg/mL and 0.1 μg/mL).
In general, gross and histologic evidence of active MARV infection was present in all non-survivors regardless of treatment status; the most common findings included macular/petechial rash, lymphoid depletion, abundant viral antigen, and necrosis, discoloration, and/or hemorrhage in multiple organs, including the liver, spleen, and kidney. The sole treated animal that succumbed with a delayed time-to-death had fewer gross lesions but more severe histologic lesions than control animals. While gastrointestinal lesions associated with MARV infection such as hemorrhage were observed in the non-survivors, evidence of gastritis, which is not typical of MARV, was also present, along with a basophilic mucosal border consistent with spirochetes. The treated survivors generally lacked gross and histologic evidence of MARV disease, and viral antigen was absent in all tissues examined. Table 3 Summary of selected clinical pathology parameters. Values are shown as mean change from baseline at day 7 for Studies 1 and 2 or day 6 for Study 3. Baseline values were those at day −3 for Study 1 or day 0 for Studies 2 and 3. The Wilcoxon rank-sum test was used for analysis of Studies 1 and 3; the Kruskal-Wallis test with Dunn's multiple comparisons test was used for Study 2. P value is compared with vehicle control group. Statistically significant P values (P < 0.05) are highlighted in bold. Abbreviations: ALT, alkaline phosphatase; ALT, alanine aminotransferase; U, units; L, liter; CRE, creatinine; mg, milligram; dL, deciliter; PT, prothrombin time; sec, seconds; DDI, D-dimers; AT, antithrombin; PLT, platelets; μL, microliter. 7.8 ± 2.1 5.9 ± 1.8 Favipiravir 125 mg/kg Loading Dose + 75 mg/kg 13 days, PO BID F 2.6 ± 3.6 5.8 ± 5.7 M1 0.6 ± 0.5 0.8 ± 0.9 Table 5 Plasma favipiravir and metabolite 1 (M1) levels in plasma from nonhuman primates in Study 3. The data are expressed as mean ± standard deviation. 14.7 ± 13.4 308.4 ± 47.5 42.6 ± 56.0 1.1 ± 1.7 M1 2.6 ± 0.8 13.2 ± 4.7 2.0 ± 1.2 15.9 ± 6.0 2.2 ± 1.2 18.2 ± 6.8 5.1 ± 5.1 0.1 ± 0.0 S.L. Bixler et al. Antiviral Research 151 (2018) 97-104 4. Discussion
During the 2013-2016 EBOV outbreak, favipiravir became an attractive therapeutic option due to its previous licensure for influenza, promising rodent and in vitro data, and the ability to utilize oral dosing regimens. However, due to the scarcity of filovirus outbreaks, the Animal Rule may be required for approval of therapeutics for filovirus disease. Therefore, the objective of this study was to determine if favipiravir provided protection against filovirus infection using the goldstandard NHP model.
Once-or twice-daily oral administration of favipiravir did not confer a survival benefit in EBOV-infected NHPs. However, the repeated anesthesia events required for once-and twice-daily oral dosing may have been a confounding factor in these studies, with a potentially deleterious effect on the survival of animals experiencing clinical manifestations of EVD. Favipiravir treatment did result in increased time-todeath, reductions in viremia, and less severe alterations in clinical measures of EVD related to liver function, clotting, hemorrhage and inflammation. Although viral RNA levels were reduced in both the once-daily and twice-daily dosing regimens, the changes were more marked following twice-daily dosing (10-vs 1000-fold). Upon withdrawal of drug on day 10 in Study 1, viremia increased and is suggestive of viral recrudescence. Moreover, once-daily administration of favipiravir increased time-to-death by 5 days, while twice-daily administration resulted in a dose-dependent increase in time-to-death by 3 and 7 days.
The absence of survival benefit in EBOV infection despite the observed reduction in viremia and less severe clinical, hematologic, pathologic, and biochemical changes is surprising but may relate to other contributing factors, including drug exposure over the entire treatment course, atypical gastrointestinal pathology, and/or opportunistic bacterial infection of the gastrointestinal tract and the adverse effects of repeated anesthesia events (see below). Typical gastrointestinal pathology associated with filoviral disease in NHPs is limited to the gastroduodenal junction or the distal colon, and is characterized by hemorrhage, congestion, and necrosis. While a subset of the lesions observed in Studies 1 and 2 where PO dosing was utilized were reminiscent of filovirus-associated pathology (i.e. hemorrhage and necrosis), the location and severity of these lesions were altered. While EBOV infection likely contributed to the gastrointestinal pathology, other factors may have exacerbated this aspect of the disease, including incomplete test article and/or vehicle absorption, altered gastrointestinal susceptibility due to test article and/or vehicle, or altered manifestation of disease due to delayed time-to-death. Additionally, upon histologic evaluation, a basophilic microvillar border, bacterial spirochetes, and evidence of a bacterial biofilm were observed within the gastrointestinal lesions. It appears that while the favipiravir-treated animals were showing improved EVD symptoms, the atypical gastrointestinal pathology and/or opportunistic bacterial infections may have contributed to the mortality of some of the EBOV-exposed animals.
While the antiviral effect of favipiravir was limited to extended time-to-death and reduced viral loads for EBOV-infected NHPs, survival significantly improved for MARV-infected NHPs treated with favipiravir, as five of the six (83%) treated animals survived. The sole treated animal that succumbed had a significantly delayed time-to-death, as well as fewer clinical and pathologic changes. The differences in efficacy for EBOV and MARV may be related to pathogenicity differences between the two filoviruses. Similar results were observed for the VEEV replicon vaccine which protected cynomolgus macaques from MARV but not EBOV (Pushko et al., 2000; Geisbert et al., 2002) . This may be due to differential disease and infection kinetics between the two viruses, as MARV animals were delayed in time-to-death and perhaps had additional time to generate a protective antiviral immune response (Geisbert et al., 2002) . The improved outcome in the MARV study could also be related to differences in the antiviral activity of favipiravir against EBOV versus MARV. Although a different virus strain was used for our in vitro studies (Ci67), we found that the MARV EC 50 (51.4 μM) was markedly lower than that of EBOV (Bixler et al., 2017) .
It is also possible that the differences in degree of protection conferred following favipiravir treatment may be related to IV versus PO administration. Favipiravir has been formulated for administration by oral dosing, which in an outbreak scenario may provide ease-of-use convenience and cost saving advantages compared to injectable medical countermeasures. Oral treatment also reduces the requirement for needle use, thus providing a safer treatment option for a disease that is easily transmitted through potential needlestick injury. In our EBOV studies in which a survival benefit was not present, favipiravir was administered orally while intravenous administration was utilized in the MARV study in which survival was observed. These results highlight the challenges associated with oral delivery, as bioavailability can reduce systemic exposure. However, plasma favipiravir levels exceeded the EC 50 (44.2 μg/mL) for inhibition of EBOV infection near the expected C max timepoints in both EBOV NHP studies (Bixler et al., 2017) . After 400 mg/kg loading plus 200 mg/kg maintenance doses once-daily or 250 mg/kg loading plus 150 mg/kg maintenance doses twice-daily, plasma drug levels near C max (159-231 μg/mL) were 4-to 6-fold the EC 50 , i.e., 44.2 μg/mL. In the 125 mg/kg loading plus 75 mg/kg maintenance dose, minimal plasma drug levels were achieved and are consistent with the modest 10-fold reduction in viremia. It is also noteworthy that irrespective of dose, time and dosing regimen, the concentrations of the major metabolite remained low, i.e., 2-37 μg/mL which suggests inhibition of the metabolizing enzyme, aldehyde oxidase, was achieved.
There is good agreement between the PK data obtained in Study 1 with the projected plasma levels predicted in a proposed clinical trial. In humans, a 2400 mg loading dose administered twice-daily resulted in a C min of 4.3 μg/mL (Mentre et al., 2015) which is comparable to the average 7 μg/mL plasma levels noted 24 h post-administration of 200 mg/kg in NHPs. The projected C avg level in humans following a 1000 mg dose twice-daily was approximately 66.8 μg/mL. In the current study, near C max levels ranged from 159 to 231 μg/mL and exceeded the targeted human C avg level but due to the sparse blood sampling post-administration a C avg level cannot be calculated.
A series of recent PK studies by Madelain et al. has also provided additional insights into the pharmacokinetic profile of IV favipiravir in NHPs with respect to dose and treatment duration . While it is difficult to directly compare those experiments to Studies 1 and 2 here due to differences in formulation, dosing regimen, and route of administration, Study 3, which utilized IV dosing of 250 mg/kg BID (loading) followed by 150 mg/kg BID (maintenance) for 14 days, mimics those studies performed by Madelain et al. Differences in systemic levels of favipiravir between the two studies may be due to differences in sampling time points, as well as the effect of filovirus infection on favipiravir pharmacokinetics. Using pharmacokinetic modeling, Madelain et al. predicted that a maintenance dose of 100 mg/kg BID would be sufficient to cover the MARV EC 50 until day 7, at which time the dose should be increased to 120 mg/kg BID from day 7 to day 14 to account for increased favipiravir clearance ; in support of this, we found that a 150 mg/kg BID maintenance dose from day 1 to day 13 was sufficient to protect NHPs from lethal MARV infection. Due to the higher EC 50 for EBOV, the authors also anticipated that EBOV studies would require a maintenance dose of 180 mg/kg BID until day 7, with an increase to ∼220 mg/kg BID from day 7 to day 14 . These findings suggest a potential explanation why improved survival was not noted in Study 2 with either dosing regimen (250/125 mg/kg BID or 125/75 mg/kg BID).
In conclusion, favipiravir is a novel synthetic guanidine nucleobase with antiviral activity against filovirus infection of NHPs. While an antiviral effect of oral favipiravir dosing was achieved for EBOV, this did not translate to a substantive survival benefit. However, a substantive survival benefit was achieved with IV favipiravir administration against MARV. This data is particularly encouraging in light of the recent MARV outbreak in Uganda in October 2017 (Marburg virus disease). Based on our results, as well as its oral delivery and safety profile, favipiravir may be an appealing prophylactic candidate for individuals with a high-risk for infection, including close contacts of confirmed cases and healthcare workers.
These studies also provide valuable information for those evaluating therapeutics in NHP models of disease. For instance, the use of a central line to avoid the need for repeated anesthesia should be considered for maximizing the performance of therapeutic candidates in NHPs, although the risks of catheter use -e.g. added behavioral stress, lesions occurring from jackets, and increased potential for secondary infections -should also be considered when designing experiments. Additional studies are needed to characterize extensions in time between viral exposure and treatment to more closely resemble treatment scenarios in a clinical setting. Further preclinical studies are also warranted to determine if IV infusion of favipiravir improves survival following EBOV infection.
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